The Power Of Partnership: Supporting Rapid Global COVID-19 Manufacture

A mid-size pharmaceutical company based in the United States (US) and Europe (EU) was developing a COVID-19 vaccine using a prioritized protocol with an extremely aggressive timeline. As a result of the product’s demonstrated safety and efficacy against the virus, this company entered into contracts with governments in the US and EU to supply millions of doses. To meet contractual demands, the company needed to ensure rapid but smooth technology transfer to multiple production sites across the world at the same time.

The company needed a partner with the expertise, capabilities, and capacity needed to navigate the main challenges of the COVID environment, including supply chain issues and the need to scale up production to meet enormous, urgent, global demand. Learn about the CDMO partnership that enabled simplified technology transfer to other sites, overcame challenges with analytical methods and equipment, and met aggressive timelines.